Business
International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting
Toronto, Ontario--(Newsfile Corp. - July 24, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TD...
About this update from Telo Genomics Corp.
[{"type":"text","content":"International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 MeetingToronto, Ontario--(Newsfile Corp. - July 24, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"Telo\") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the International Myeloma Society (\"IMS\") has accepted Telo Genomics' abstract submission for a poster presentation on minimal residual disease (\"MRD\") during the upcoming 22nd International Myeloma Society Annual Meeting in Toronto, Canada.The new abstract titled, \"3D Telomere Profiling of MRD (Minimal Residual Disease) in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression,\" will be presented at the meeting by Dr. Yulia Shifrin, Laboratory Director of Telo Genomics and published in Clinical Lymphoma, Myeloma & Leukemia. The abstract entails a technical methodology of MRD assessment based on TeloView profiling. Details of the abstract will be provided after the poster session. TeloView MM-MRD's proprietary approach of counting and profiling individual MRD cells has the potential to provide actionable information on risk of relapse to clinicians.The International Myeloma Society (IMS) is a global professional organization dedicated to advancing the science and treatment of multiple myeloma. Its upcoming 22nd Annual Meeting, will take place from September 17-20, 2025. IMS meetings are widely considered as a defining annual forum in the myeloma field.\"We are excited to share the next clinical application of our 3D telomere application for MRD for multiple myeloma at IMS,\" said Dr. Sabine Mai, Telo's Co-Founder. \"The acceptance is a result of our commitment to develop a clinical offering and a novel approach of liquid biopsy MRD.\" The Company announces that, further to its news release dated February 27, 2025, the Company has issued an aggregate of 411,539 common shares (\"Shares\") to Trusted Health Advisors LLC (\"THA\"), to compensate THA for its provision of services related to the partnering and commercialization of Telo's diagnostic technologies from January to July 1, 2025. Pursuant to the agreement between THA and the Company, 214,605 Shares were issued at a deemed price of $0.12 per Share, and 196,934 Shares were issued at a ...